Literature DB >> 23534598

[Systemic lupus erythematosus and pregnancy].

Teresa Diniz-da-Costa1, Mónica Centeno, Luísa Pinto, Aurora Marques, Luís Mendes-Graça.   

Abstract

Systemic lupus erythematosus is a chronic inflammatory disease, resulting from an auto-immune dysfunction. The etiology of this disease is unknown. It frequently occurs in women of childbearing age. Pregnancy in patients with systemic lupus erythematosus may be associated with several complications (maternal, obstetrical and fetal). The prognosis for both mother and child is better when systemic lupus erythematosus has been quiescent for at least six months before pregnancy. Thus, preconceptional assessment and management is crucial for helping women to achieve a period of disease remission before pregnancy as well as for allowing an adjustment of therapy. Maternal health and fetal development should be closely monitored during pregnancy. These patients should be surveilled by a multidisciplinary team (obstetrician, rheumatologist or internist, nephrologist if necessary and a pediatrician), in a tertiary care hospital. Antiphospholipid syndrome, positivity for anti-SSA/Ro or anti-SSB/LA antibodies, hypertension or renal involvement are associated with an increase of adverse pregnancy outcomes. In this article the authors review the main aspects of Systemic lupus erythematosus (SLE) and pregnancy.

Entities:  

Mesh:

Year:  2013        PMID: 23534598

Source DB:  PubMed          Journal:  Acta Med Port        ISSN: 0870-399X


  3 in total

1.  Diagnostic accuracy of miRNAs as potential biomarkers for systemic lupus erythematosus: a meta-analysis.

Authors:  Zi-Wei Dai; Hong Wang; Wen-Juan Xu; Zhi-Hui Wang; Sheng-Qian Xu; Bin Wang; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2018-07-06       Impact factor: 2.980

Review 2.  Autoimmune diseases and pregnancy: analysis of a series of cases.

Authors:  Vânia Gomes; Alexandra Mesquita; Carlos Capela
Journal:  BMC Res Notes       Date:  2015-06-04

3.  Prognosis in Pregnant Females With Systemic Lupus Erythematosus.

Authors:  Enling Liu; Yuxiu Zhou
Journal:  Arch Rheumatol       Date:  2017-04-21       Impact factor: 1.472

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.